Sanofi: FDA approves Dupixent

(CercleFinance.com) - Sanofi announced on Tuesday evening that the FDA has approved Dupixent (dupilumab), a biologic drug for the treatment of moderate-to-severe atopic dermatitis in children aged 6 to 11.


"In the pivotal trial, more than twice as many children achieved clear or almost clear skin and more than four times achieved itch reduction with Dupixent plus topical corticosteroids (TCS) compared to TCS alone. Three-quarters of patients receiving Dupixent achieved at least a 75% improvement in overall disease, with an average improvement of approximately 80%," Sanofi said.


Copyright (c) 2020 CercleFinance.com. All rights reserved.